EP3873932A4 - Procédés et compositions pour l'imagerie de dépôts d'amyloïde - Google Patents

Procédés et compositions pour l'imagerie de dépôts d'amyloïde Download PDF

Info

Publication number
EP3873932A4
EP3873932A4 EP19880738.0A EP19880738A EP3873932A4 EP 3873932 A4 EP3873932 A4 EP 3873932A4 EP 19880738 A EP19880738 A EP 19880738A EP 3873932 A4 EP3873932 A4 EP 3873932A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
amyloid deposits
imaging amyloid
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19880738.0A
Other languages
German (de)
English (en)
Other versions
EP3873932A1 (fr
Inventor
Suzanne Lentzsch
Akiva Mintz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of EP3873932A1 publication Critical patent/EP3873932A1/fr
Publication of EP3873932A4 publication Critical patent/EP3873932A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP19880738.0A 2018-10-31 2019-10-30 Procédés et compositions pour l'imagerie de dépôts d'amyloïde Pending EP3873932A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862753410P 2018-10-31 2018-10-31
PCT/US2019/058720 WO2020092474A1 (fr) 2018-10-31 2019-10-30 Procédés et compositions pour l'imagerie de dépôts d'amyloïde

Publications (2)

Publication Number Publication Date
EP3873932A1 EP3873932A1 (fr) 2021-09-08
EP3873932A4 true EP3873932A4 (fr) 2022-11-23

Family

ID=70462389

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19880738.0A Pending EP3873932A4 (fr) 2018-10-31 2019-10-30 Procédés et compositions pour l'imagerie de dépôts d'amyloïde

Country Status (3)

Country Link
EP (1) EP3873932A4 (fr)
JP (2) JP7337922B2 (fr)
WO (1) WO2020092474A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100427505C (zh) * 2004-08-19 2008-10-22 中国医学科学院基础医学研究所 抗人肿瘤坏死因子相关凋亡诱导配体的受体dr5单克隆抗体（ad5-10）及其制法与用途
US20090297439A1 (en) 2008-06-02 2009-12-03 Metheresis Translational Research Sa, Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis, corresponding compositions and kits
CA2956820A1 (fr) 2014-08-26 2016-03-03 University Of Tennessee Research Foundation Immunotherapie de ciblage de l'amyloidose
US10822410B2 (en) * 2016-11-23 2020-11-03 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
CA3067597C (fr) 2017-06-29 2023-03-21 The Trustees Of Columbia University In The City Of New York Anticorps chimeriques pour le traitement de maladies de depot amyloide

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
SOLOMON ALAN ET AL: "Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, US, vol. 9, no. 10 Pt 2, 1 September 2003 (2003-09-01), pages 3831S - 3838S, XP002486752, ISSN: 1078-0432, DOI: HTTPS://CLINCANCERRES.AACRJOURNALS.ORG/CONTENT/9/10/3831S *
WALL JONATHAN S ET AL: "Development and evaluation of agents for targeting visceral amyloid", TIJDSCHRIFT VOOR NU[C]LEAIRE GENEESKUNDE, vol. 33, no. 4, 1 December 2011 (2011-12-01), Netherlands, pages 807, XP055574438, ISSN: 1381-4842 *
WALL JONATHAN S ET AL: "Radioimaging of Light Chain Amyloid with a Fibril-Reactive Monoclonal Antibody", THE JOURNAL OF NUCLEAR MEDICINE, vol. 47, no. 12, 30 November 2006 (2006-11-30), pages 2016 - 2024, XP055970051 *
WALL JONATHAN S ET AL: "Radioimmunodetection of amyloid deposits in patients with AL amyloidosis", BLOOD, vol. 116, no. 13, 30 September 2010 (2010-09-30), US, pages 2241 - 2244, XP055969810, ISSN: 0006-4971, DOI: 10.1182/blood-2010-03-273797 *

Also Published As

Publication number Publication date
JP2022512892A (ja) 2022-02-07
WO2020092474A1 (fr) 2020-05-07
JP7337922B2 (ja) 2023-09-04
EP3873932A1 (fr) 2021-09-08
JP2023093673A (ja) 2023-07-04

Similar Documents

Publication Publication Date Title
SG11202008659TA (en) Cartyrin compositions and methods for use
IL280134A (en) Anti-CD112R preparations and methods
EP3803403A4 (fr) Compositions et procédés d'imagerie
IL282225A (en) Preparations and methods for immunotherapy
EP3764766A4 (fr) Imagerie de graines
EP3852631A4 (fr) Procédé d'imagerie
EP3826673A4 (fr) Compositions et procédés d'imagerie
SG11202104448WA (en) Compositions and methods
EP3810109A4 (fr) Compositions et procédés d'inhibition de cd73
IL283644A (en) Preparations and methods for immunotherapy
EP3844500A4 (fr) Compositions de rp182 et procédés
EP3807319A4 (fr) Compositions et procédés pour induire une phagocytose
EP3801534A4 (fr) Compositions et procédés pour augmenter l'exposition au plasma de tétrahydrobioptérine
EP3805832A4 (fr) Dispositif d'imagerie
EP3766428A4 (fr) Dispositif d'imagerie
EP3791620A4 (fr) Procédés et appareils destinés à une exposition de capacité
EP3638277A4 (fr) Compositions et procédés d'inhibition de la bêta-sécrétase
EP3866810A4 (fr) Procédés et compositions pour le traitement de la mucosite buccale
EP3812837A4 (fr) Dispositif d'imagerie
GB201817444D0 (en) Methods and compositions
EP3894544A4 (fr) Compositions et méthodes pour l'immunosuppression
SG11202012487WA (en) Methods and compositions for somatic variant detection
EP3681520A4 (fr) Compositions et méthodes permettant de traiter une maladie hépatique et un dysfonctionnement hépatique
EP3873932A4 (fr) Procédés et compositions pour l'imagerie de dépôts d'amyloïde
EP3856184A4 (fr) Compositions et méthodes pour inhiber acss2

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210528

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40059059

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07K0016180000

Ipc: A61K0051100000

A4 Supplementary search report drawn up and despatched

Effective date: 20221024

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 103/00 20060101ALI20221018BHEP

Ipc: A61K 101/02 20060101ALI20221018BHEP

Ipc: A61K 39/395 20060101ALI20221018BHEP

Ipc: C07K 16/18 20060101ALI20221018BHEP

Ipc: A61K 51/10 20060101AFI20221018BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230314